ajanta pharma limited

Regd.Office: 'Ajanta House', Charkop, Kandivli (W), Mumbai-67, Phone - +91-22-66061000, Fax - +91-22-66061200 CIN - L24230MH1979PLC022059, Email - info@ajantapharma.com, Website - www.ajantapharma.com

Statement of Consolidated Unaudited Financial Results for the quarter ended 30 June 2015

					₹ in Crore
	Particulars		3 months ended		Year Ended
		30/06/2015	31/03/2015	30/06/2014	31/03/2015
		Unaudited	Audited (Refer note 6)	Unaudited	Audited
1	Income from Operations:				
	(a) Gross Sales				
	India	148.23	116.83	121.68	491.53
	Outside India	241.52	251.74	195.98	973.10
	Total	389.75	368.57	317.66	1,464.63
	Less : Excise Duty	4.10	2,90	2.62	11.65
	Net Sales	385.65	365.67	315.04	1,452.98
	(b) Other operating income	5.70	8.48	6.70	27.58
	Total Income from Operations (net)	391.35	374.15	321.74	1,480.56
2	Expenditure				
	(a) Cost of materials consumed	79.39	70.27	58.77	324.97
	(b) Purchases of stock-in-trade	12.83	3.02	6.48	33.11
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	11.14	16.34	14.46	7.34
Н	(d) Employees benefits expense	59.19	54.69	45.97	200.58
Н	(e) Depreciation and amortisation expense	10.31	13.23	12.55	51.64
П	(f) Other expenses	106.24	96.74	99.14	409.33
	Total expenses	279.10	254.29	237.37	1,026.97
3	Profit from operations before other income, finance costs & tax (1-2)	112.25	119.86	84.37	453.59
4	(a) Other Income	3.02	2.88	2.56	12.66
<u>*</u>	(b) Exchange rate difference (Net)	3.56	2.10	1.95	4.14
5	Profit from ordinary activities before finance costs & tax (3+4)	118.83	124.84	88.88	470.39
6	Finance costs	1.17	1.49	1.57	5.92
7	Profit from ordinary activities before exceptional item (5-6)	117.66	123,35	87.31	464.47
8	Exceptional Item		8.46	*	8.46
9	Profit from ordinary activities after exceptional item but before tax (7-8)	117.66	114.89	87.31	456.01
10	Tax Expense	33.82	40.75	27.65	146.15
11	Net Profit for the period (9-10)	83.84	74.14	59.66	309.86
	Paid-up Equity Share Capital	17.69	17.68	17.68	17.68
Ē	Face value of Equity Share - in ₹	2	2	5	2
13	Reserve excluding Revaluation Reserves	NA	NA	NA	823.41
	Earnings Per Share - not annualised (refer note 3)				
Ť	(a) Basic - in ₹	9.53	8,43	6.79	35.24
	(b) Diluted - in ₹	9.53	8.42	6.78	35.20



Д	PARTICULARS OF SHAREHOLDING				
1	Public Shareholding				
	- Number of shares	23,071,491	23,013,741	9,305,495	23,013,741
	- Percentage of shareholding	26.22%	26.17%	26.45%	26.179
T	Promoters and promoter group shareholding				
	a) Pledged/Encumbered				
	- Number of shares	1,000,000	1,051,250	1,445,500	1,051,250
	- Percentage of shares (as a % of the total	1.54%	1.62%	5.59%	1.62%
П	shareholding of promoter and promoter group)	1.54%			
Ī	- Percentage of shares (as a % of the total share	1.14%	1.20%	4.11%	1.209
	capital of the company)	1.14/0			
	b) Non-encumbered				
	- Number of shares	63,929,759	63,878,509	24,426,405	63,878,509
	- Percentage of shares (as a % of the total	98.46%	98.38%	94.41%	98.38
	shareholding of promoter and promoter group)	70.40%	90.30%	74.41/0	90.30
	- Percentage of shares (as a % of the total share	72.64%	72.63%	69.44%	72.639
	capital of the company)	72.04%	72.03%	07.44%	72.03,
3	INVESTOR COMPLAINTS		3 Months ended	30/06/2015	
	Pending at the beginning of the quarter and remaining		Ni		
	unresolved at the end of the quarter				
	Received and disposed off during the quarter		25		
	Notes: Above results have been reviewed by Audit Committee				
	13 August 2015. Consolidated financial results includes financial results of subsidiary prepared in accordance with AS 21.	the company, its w	holly owned sub	sidiaries and ste	p-down
2	Consolidated financial results includes financial results of subsidiary prepared in accordance with AS 21. Company's equity shares of the face value of ₹ 5/- each w during March, 2015. Consequently, as required by AS 20, t	as split into the equ he Earning per shar	ity shares of the	e face value of ₹	2/- each
2	Consolidated financial results includes financial results of subsidiary prepared in accordance with AS 21. Company's equity shares of the face value of ₹ 5/- each w	as split into the equ he Earning per shan d here in above. e allotted upon exer	nity shares of the e has been discl rcise of vested s	e face value of ₹ osed considering tock options pur	2/- each g increased suant to ESOS
3	Consolidated financial results includes financial results of subsidiary prepared in accordance with AS 21. Company's equity shares of the face value of ₹ 5/- each w during March, 2015. Consequently, as required by AS 20, t number of shares post sub-division, for all periods reported During the quarter 57,750 equity shares fully paid-up were 2011, including bonus, resulting in increase in paid-up shares.	as split into the equ he Earning per shar d here in above. e allotted upon exe re capital by ₹0.01	nity shares of the e has been discl rcise of vested s cr. and share pr	e face value of ₹ osed considering tock options pur	2/- each g increased suant to ESOS
2 3 4 5 6	Consolidated financial results includes financial results of subsidiary prepared in accordance with AS 21. Company's equity shares of the face value of ₹ 5/- each w during March, 2015. Consequently, as required by AS 20, t number of shares post sub-division, for all periods reported During the quarter 57,750 equity shares fully paid-up were 2011, including bonus, resulting in increase in paid-up shad The group operates exclusively in one reportable business Figures for the quarter ended 31 March 2015 are the balar 31 March 2015 and unaudited year to date figures for nine	as split into the equ he Earning per shar d here in above. e allotted upon exe re capital by ₹0.01 segment i.e., "Phan acing figures betwee months period end	nity shares of the e has been discl rcise of vested s cr. and share pr rmaceuticals". en audited figure ed 31 December	e face value of ₹ osed considering tock options pur emium by ₹0.28 es for the financ	2/- each g increased suant to ESOS cr. ial year ended
2 3 4 5 6	Consolidated financial results includes financial results of subsidiary prepared in accordance with AS 21. Company's equity shares of the face value of ₹ 5/- each w during March, 2015. Consequently, as required by AS 20, to number of shares post sub-division, for all periods reported During the quarter 57,750 equity shares fully paid-up were 2011, including bonus, resulting in increase in paid-up shares group operates exclusively in one reportable business Figures for the quarter ended 31 March 2015 are the balar	as split into the equiple Earning per shared here in above. e allotted upon exert capital by ₹0.01 segment i.e., "Phared in a segment i.e., "Phared figures between months period end results from current	rcise of vested s cr. and share pr rmaceuticals". en audited figure ed 31 December	e face value of ₹ osed considering tock options pur emium by ₹0.28 es for the financ 2014. to option made	2/- each g increased suant to ESOS cr. ial year endec available as the company's
2 3 4 5 6	Consolidated financial results includes financial results of subsidiary prepared in accordance with AS 21. Company's equity shares of the face value of ₹ 5/- each w during March, 2015. Consequently, as required by AS 20, t number of shares post sub-division, for all periods reported During the quarter 57,750 equity shares fully paid-up were 2011, including bonus, resulting in increase in paid-up shaded and the group operates exclusively in one reportable business Figures for the quarter ended 31 March 2015 are the balar 31 March 2015 and unaudited year to date figures for nine The Company has opted to publish consolidated financial per clause 41 of the listing agreement. The Standalone Figures	as split into the equiple Earning per shared here in above. e allotted upon exert re capital by ₹0.01 segment i.e., "Phared in a segment i.e., and the control of the con	rcise of vested s cr. and share pr rmaceuticals". en audited figure ed 31 December year, pursuant limited review a	e face value of ₹ osed considering tock options pur emium by ₹0.28 es for the financ 2014. to option made	2/- each g increased suant to ESOS cr. ial year endec available as the company
2 3 4 5 7	Consolidated financial results includes financial results of subsidiary prepared in accordance with AS 21. Company's equity shares of the face value of ₹ 5/- each w during March, 2015. Consequently, as required by AS 20, t number of shares post sub-division, for all periods reported During the quarter 57,750 equity shares fully paid-up were 2011, including bonus, resulting in increase in paid-up shat The group operates exclusively in one reportable business Figures for the quarter ended 31 March 2015 are the balar 31 March 2015 and unaudited year to date figures for nine The Company has opted to publish consolidated financial per clause 41 of the listing agreement. The Standalone Finwebsite www.ajantapharma.com	as split into the equiple Earning per shared here in above. e allotted upon exert re capital by ₹0.01 segment i.e., "Phared in a segment i.e., and the control of the con	rcise of vested s cr. and share pr rmaceuticals". en audited figure ed 31 December year, pursuant limited review a	e face value of ₹ osed considering tock options pur emium by ₹0.28 es for the financ 2014. to option made	2/- each g increased suant to ESOS cr. ial year endect available as the company' ₹ in Crore Year Ended
2 3 4 5 6	Consolidated financial results includes financial results of subsidiary prepared in accordance with AS 21. Company's equity shares of the face value of ₹ 5/- each w during March, 2015. Consequently, as required by AS 20, t number of shares post sub-division, for all periods reported During the quarter 57,750 equity shares fully paid-up were 2011, including bonus, resulting in increase in paid-up shat The group operates exclusively in one reportable business Figures for the quarter ended 31 March 2015 are the balar 31 March 2015 and unaudited year to date figures for nine The Company has opted to publish consolidated financial per clause 41 of the listing agreement. The Standalone Finwebsite www.ajantapharma.com Standalone Results are as under:	as split into the equiple Earning per shared here in above. e allotted upon exert re capital by ₹0.01 segment i.e., "Phared in a segment i.e., and the control of the con	rcise of vested s cr. and share promaceuticals". en audited figure ed 31 December syear, pursuant limited review a	e face value of ₹ osed considering tock options pur emium by ₹0.28 es for the financ 2014. to option made	2/- each g increased suant to ESOS cr. ial year endec available as the company's
2 3 4 5	Consolidated financial results includes financial results of subsidiary prepared in accordance with AS 21. Company's equity shares of the face value of ₹ 5/- each w during March, 2015. Consequently, as required by AS 20, t number of shares post sub-division, for all periods reported During the quarter 57,750 equity shares fully paid-up were 2011, including bonus, resulting in increase in paid-up shat The group operates exclusively in one reportable business Figures for the quarter ended 31 March 2015 are the balar 31 March 2015 and unaudited year to date figures for nine The Company has opted to publish consolidated financial per clause 41 of the listing agreement. The Standalone Finwebsite www.ajantapharma.com Standalone Results are as under:	as split into the equipe Earning per shared here in above. e allotted upon exerging the capital by ₹0.01 segment i.e., "Phared figures between months period end results from current nancial Results with	rcise of vested s cr. and share pr rmaceuticals". en audited figure ed 31 December year, pursuant limited review a	e face value of ₹ osed considering tock options pur emium by ₹0.28 es for the finance 2014. to option made are available on 30/06/2014 Unaudited	2/- each g increased suant to ESOS cr. ial year ended available as the company' ₹ in Cron Year Ended 31/03/2015 Audited
2 3 4 5 6	Consolidated financial results includes financial results of subsidiary prepared in accordance with AS 21. Company's equity shares of the face value of ₹ 5/- each w during March, 2015. Consequently, as required by AS 20, t number of shares post sub-division, for all periods reported During the quarter 57,750 equity shares fully paid-up were 2011, including bonus, resulting in increase in paid-up shat The group operates exclusively in one reportable business Figures for the quarter ended 31 March 2015 are the balar 31 March 2015 and unaudited year to date figures for nine The Company has opted to publish consolidated financial per clause 41 of the listing agreement. The Standalone Finwebsite www.ajantapharma.com Standalone Results are as under:	as split into the equipe Earning per shared here in above. e allotted upon exerting re capital by ₹0.01 segment i.e., "Phared figures between months period end results from current nancial Results with	rcise of vested s cr. and share promaceuticals". en audited figure ed 31 December syear, pursuant limited review a	e face value of ₹ osed considering tock options pur emium by ₹0.28 es for the finance 2014. to option made are available on 30/06/2014 Unaudited 287.49	2/- each g increased suant to ESOS cr. ial year endec available as the company's ₹ in Crore Year Ended 31/03/2015 Audited 1,356.20
2 3 4 5 6	Consolidated financial results includes financial results of subsidiary prepared in accordance with AS 21. Company's equity shares of the face value of ₹ 5/- each w during March, 2015. Consequently, as required by AS 20, t number of shares post sub-division, for all periods reported During the quarter 57,750 equity shares fully paid-up were 2011, including bonus, resulting in increase in paid-up shat The group operates exclusively in one reportable business Figures for the quarter ended 31 March 2015 are the balar 31 March 2015 and unaudited year to date figures for nine The Company has opted to publish consolidated financial per clause 41 of the listing agreement. The Standalone Finwebsite www.ajantapharma.com Standalone Results are as under: Particulars Total Income from Operations (net)	as split into the equipe Earning per shared here in above. e allotted upon exerting re capital by ₹0.01 segment i.e., "Phared figures between months period end results from current nancial Results with \$30/06/2015 Unaudited	rcise of vested s cr. and share pr maceuticals". en audited figure ed 31 December year, pursuant limited review a months ended 31/03/2015 Audited 368.84 122.97	e face value of ₹ osed considering tock options pur emium by ₹0.28 es for the finance 2014. to option made are available on 30/06/2014 Unaudited	2/- each g increased suant to ESOS cr. ial year ended available as the company' ₹ in Crore Year Ended 31/03/2015 Audited 1,356.20 444.88
2 3 4 5 6	Consolidated financial results includes financial results of subsidiary prepared in accordance with AS 21. Company's equity shares of the face value of ₹ 5/- each w during March, 2015. Consequently, as required by AS 20, t number of shares post sub-division, for all periods reported During the quarter 57,750 equity shares fully paid-up were 2011, including bonus, resulting in increase in paid-up shat The group operates exclusively in one reportable business Figures for the quarter ended 31 March 2015 are the balar 31 March 2015 and unaudited year to date figures for nine The Company has opted to publish consolidated financial per clause 41 of the listing agreement. The Standalone Finwebsite www.ajantapharma.com Standalone Results are as under: Particulars Total Income from Operations (net)	as split into the equipe Earning per shared here in above. e allotted upon exerting re capital by ₹0.01 segment i.e., "Phared figures between months period end results from current mancial Results with 30/06/2015 Unaudited 340.58	rcise of vested s cr. and share pr maceuticals". en audited figure ed 31 December year, pursuant limited review a months ended 31/03/2015 Audited 368.84	e face value of ₹ osed considering tock options pur emium by ₹0.28 es for the finance 2014. to option made are available on 30/06/2014 Unaudited 287.49	2/- each g increased suant to ESOS cr. ial year ended available as the company' ₹ in Crore Year Ended 31/03/2015 Audited 1,356.20 444.88
22 33 44 55 77	Consolidated financial results includes financial results of subsidiary prepared in accordance with AS 21. Company's equity shares of the face value of ₹ 5/- each w during March, 2015. Consequently, as required by AS 20, t number of shares post sub-division, for all periods reported During the quarter 57,750 equity shares fully paid-up were 2011, including bonus, resulting in increase in paid-up shat The group operates exclusively in one reportable business Figures for the quarter ended 31 March 2015 are the balar 31 March 2015 and unaudited year to date figures for nine The Company has opted to publish consolidated financial per clause 41 of the listing agreement. The Standalone Finwebsite www.ajantapharma.com Standalone Results are as under: Particulars Total Income from Operations (net)	as split into the equipe Earning per shared here in above. e allotted upon exerting re capital by ₹0.01 segment i.e., "Phared figures between months period end results from current nancial Results with 3 30/06/2015 Unaudited 340.58 112.61 81.06	rcise of vested s cr. and share pr maceuticals". en audited figure ed 31 December year, pursuant limited review a months ended 31/03/2015 Audited 368.84 122.97	e face value of tosed considering tock options pure mium by ₹0.28 es for the finance 2014. to option made are available on 30/06/2014 Unaudited 287.49 84.93 58.72	2/- each 3 increased suant to ESOS cr. ial year endect available as the company' ₹ in Crore Year Ended 31/03/2015 Audited 1,356.20 444.88 306.37
2 3 4 5 7	Consolidated financial results includes financial results of subsidiary prepared in accordance with AS 21. Company's equity shares of the face value of ₹ 5/- each w during March, 2015. Consequently, as required by AS 20, t number of shares post sub-division, for all periods reported During the quarter 57,750 equity shares fully paid-up were 2011, including bonus, resulting in increase in paid-up shat The group operates exclusively in one reportable business Figures for the quarter ended 31 March 2015 are the balar 31 March 2015 and unaudited year to date figures for nine The Company has opted to publish consolidated financial per clause 41 of the listing agreement. The Standalone Finwebsite www.ajantapharma.com Standalone Results are as under: Particulars Total Income from Operations (net) Profit Before Tax Profit After Tax	as split into the equipe Earning per shared here in above. e allotted upon exerting re capital by ₹0.01 segment i.e., "Phared figures between months period end results from current nancial Results with 3 30/06/2015 Unaudited 340.58 112.61 81.06	rcise of vested s cr. and share pr maceuticals". en audited figure ed 31 December year, pursuant limited review a months ended 31/03/2015 Audited 368.84 122.97	e face value of tosed considering tock options puremium by \$0.28 es for the finance 2014. to option made are available on 30/06/2014 Unaudited 287.49 84.93 58.72	2/- each 3 increased suant to ESOS cr. ial year ended available as the company' ₹ in Cror Year Ended 31/03/2015 Audited 1,356.20 444.88 306.37 er of the Boar
2 3 4 5 6 7	Consolidated financial results includes financial results of subsidiary prepared in accordance with AS 21. Company's equity shares of the face value of ₹ 5/- each w during March, 2015. Consequently, as required by AS 20, t number of shares post sub-division, for all periods reported During the quarter 57,750 equity shares fully paid-up were 2011, including bonus, resulting in increase in paid-up shat The group operates exclusively in one reportable business Figures for the quarter ended 31 March 2015 are the balar 31 March 2015 and unaudited year to date figures for nine The Company has opted to publish consolidated financial per clause 41 of the listing agreement. The Standalone Finwebsite www.ajantapharma.com Standalone Results are as under: Particulars Total Income from Operations (net) Profit Before Tax Profit After Tax	as split into the equipe Earning per shared here in above. e allotted upon exerting re capital by ₹0.01 segment i.e., "Phared figures between months period end results from current mancial Results with 30/06/2015 Unaudited 340.58 112.61 81.06 eccessary.	rcise of vested scr. and share promaceuticals. en audited figure ed 31 December syear, pursuant limited review at 103/2015 Audited 368.84 122.97 84.31	e face value of tosed considering tock options puremium by \$0.28 es for the finance 2014. to option made are available on 30/06/2014 Unaudited 287.49 84.93 58.72	2/- each 3 increased suant to ESOS cr. ial year ended available as the company' ₹ in Cror Year Ended 31/03/2015 Audited 1,356.20 444.88 306.37 er of the Boar
2 3 4 5 6 7	Consolidated financial results includes financial results of subsidiary prepared in accordance with AS 21. Company's equity shares of the face value of ₹ 5/- each w during March, 2015. Consequently, as required by AS 20, t number of shares post sub-division, for all periods reported During the quarter 57,750 equity shares fully paid-up were 2011, including bonus, resulting in increase in paid-up shat The group operates exclusively in one reportable business Figures for the quarter ended 31 March 2015 are the balar 31 March 2015 and unaudited year to date figures for nine The Company has opted to publish consolidated financial per clause 41 of the listing agreement. The Standalone Finwebsite www.ajantapharma.com Standalone Results are as under: Particulars Total Income from Operations (net) Profit Before Tax Profit After Tax	as split into the equipe Earning per shared here in above. e allotted upon exerting re capital by ₹0.01 segment i.e., "Phared figures between months period end results from current mancial Results with 30/06/2015 Unaudited 340.58 112.61 81.06 eccessary.	rcise of vested scr. and share promaceuticals. en audited figure ed 31 December syear, pursuant limited review at 103/2015 Audited 368.84 122.97 84.31	e face value of tosed considering tock options puremium by ₹0.28 es for the finance 2014. to option made are available on 30/06/2014 Unaudited 287.49 84.93 58.72 By order For Ajant	2/- each g increased suant to ESOS cr. ial year endect available as the company's ₹ in Crore Year Ended 31/03/2015 Audited 1,356.20 444.88 306.37 er of the Boar ta Pharma Ltd
2 3 4 5 6 7	Consolidated financial results includes financial results of subsidiary prepared in accordance with AS 21. Company's equity shares of the face value of ₹ 5/- each w during March, 2015. Consequently, as required by AS 20, t number of shares post sub-division, for all periods reported During the quarter 57,750 equity shares fully paid-up were 2011, including bonus, resulting in increase in paid-up shat The group operates exclusively in one reportable business Figures for the quarter ended 31 March 2015 are the balar 31 March 2015 and unaudited year to date figures for nine The Company has opted to publish consolidated financial per clause 41 of the listing agreement. The Standalone Finwebsite www.ajantapharma.com Standalone Results are as under: Particulars Total Income from Operations (net) Profit Before Tax Profit After Tax	as split into the equipe Earning per shared here in above. e allotted upon exerting re capital by ₹0.01 segment i.e., "Phared figures between months period end results from current mancial Results with 30/06/2015 Unaudited 340.58 112.61 81.06 eccessary.	rcise of vested s cr. and share pr maceuticals". en audited figure ed 31 December year, pursuant limited review a months ended 31/03/2015 Audited 368.84 122.97	e face value of tosed considering tock options puremium by \$0.28 es for the finance 2014. to option made are available on 30/06/2014 Unaudited 287.49 84.93 58.72	2/- each g increased suant to ESOS cr. ial year endect available as the company's ₹ in Crore Year Ended 31/03/2015 Audited 1,356.20 444.88 306.37 er of the Boarda Pharma Ltd
2 3 4 5 6 7	Consolidated financial results includes financial results of subsidiary prepared in accordance with AS 21. Company's equity shares of the face value of ₹ 5/- each w during March, 2015. Consequently, as required by AS 20, t number of shares post sub-division, for all periods reported During the quarter 57,750 equity shares fully paid-up were 2011, including bonus, resulting in increase in paid-up shat The group operates exclusively in one reportable business Figures for the quarter ended 31 March 2015 are the balar 31 March 2015 and unaudited year to date figures for nine The Company has opted to publish consolidated financial per clause 41 of the listing agreement. The Standalone Finwebsite www.ajantapharma.com Standalone Results are as under: Particulars Total Income from Operations (net) Profit Before Tax Profit After Tax	as split into the equipe Earning per shared here in above. e allotted upon exerting re capital by ₹0.01 segment i.e., "Phared figures between months period end results from current mancial Results with 30/06/2015 Unaudited 340.58 112.61 81.06 eccessary.	rcise of vested scr. and share promaceuticals. en audited figure ed 31 December syear, pursuant limited review at 103/2015 Audited 368.84 122.97 84.31	e face value of tosed considering tock options puremium by ₹0.28 es for the finance 2014. to option made are available on 30/06/2014 Unaudited 287.49 84.93 58.72 By order For Ajant Yoge	2/- each g increased suant to ESOS cr. ial year endect available as the company's ₹ in Crore Year Ended 31/03/2015 Audited 1,356.20 444.88 306.37 er of the Boarda Pharma Ltd

ajanta pharma limited

Regd.Office: 'Ajanta House', Charkop, Kandivli (W), Mumbai-67, Phone - +91-22-66061000, Fax - +91-22-66061200 CIN - L24230MH1979PLC022059, Email - info@ajantapharma.com, Website - www.ajantapharma.com

_	Statement of Standalone Unaudited Financia	100000000000000000000000000000000000000		- Joseph			
	Particulars		3 months ended		₹ in C		
		30/06/2015	31/03/2015	30/06/2014	Year End 31/03/20		
			Audited	5070072014	31/03/20		
		Unaudited	(Refer note 6)	Unaudited	Audited		
Inc	ome from Operations:		(Merer noce of				
(a)	Gross Sales						
	India	148.23	116,83	124 (0	404		
	Outside India	190,75	246.43	121.68	491		
	Total			161,73	848		
	Less : Excise Duty	338.98	363.26	283.41	1,340		
	Net Sales	4.10	2,90	2.62	11		
(b) (Other operating income	334.88	360.36	280.79	1,328		
-		5.70	8.48	6.70	27		
-	al Income from Operations (net)	340,58	368.84	287.49	1,356.		
terrip.	enditure	11-1-0-11949					
	Cost of materials consumed	77.86	73.34	57.82	321		
	Purchases of stock-in-trade	13.96	15,46	10,01	50		
(c) (Changes in inventories of finished goods,				30		
٧	work-in-progress and stock-in-trade	2.30	14,53	12.48	9		
(d) E	Employees benefits expense	54,55	50.81	42,84	101		
(e) [Depreciation and amortisation expense	9.70	12.59		186		
(f) O	Other expenses	82,10		12.04	49		
	al expenses	240.47	73.98	74.64	316		
Prof	it from operations before other income, finance	240.47	240.71	209.83	933.		
cost	s & tax (1-2)	100.11	128.13	77.66	423		
	Other Income		120,15	//.00	423		
		12,23	2.34	8.58	29		
(D) E	xchange rate difference (Net)	1.30	0,50	0,11	4		
Prof	it from ordinary activities before finance costs & tax	442.4					
(3+4	,	113.64	130.97	86.35	456.		
	nce costs	1.03	1.05	1,42	5.		
Profi	it from ordinary activities before exceptional item (5-		// **	1.72	J.		
6)		112,61	129.92	84.93	451.		
Exce	ptional Item		(05				
Profi	it from ordinary activities after exceptional item but		6.95	*	6.		
befor	re tax (7-8)	112.61	122.97	84,93	444.		
Tax F	xpense				7-1-1,		
15,077,000	Profit for the period (9-10)	31.55	38.66	26,21	138.		
		81.06	84.31	58.72	306.		
Caro.	up Equity Share Capital	17.69	17.68	17.68	17.		
race	value of Equity Share - in ₹	2	2	5			
Reser	rve excluding Revaluation Reserves	NA	NA	NA	768.		
	ngs Per Share - not annualised (refer note 3)				700.		
(a) Ba	asic - in ₹	9.21	9,59	6.68	24		
(b) Di	iluted - in ₹	9,21	9.58	6.67	34.		
PARTI	ICULARS OF SHAREHOLDING		7,36	0.07	34.		
	c Shareholding						
- N	lumber of shares	22.074.404	22 242 744				
	ercentage of shareholding	23,071,491	23,013,741	9,305,495	23,013,7		
Dromo	oters and promoter group shareholding	26.22%	26.17%	26.45%	26.1		
a) Dia	oters and promoter group snarenotding						
	dged/Encumbered						
	umber of shares	1,000,000	1,051,250	1,445,500	1,051,25		
- Pe	ercentage of shares (as a % of the total	4 5 454			1,051,22		
sh	areholding of promoter and promoter group)	1.54%	1.62%	5.59%	1.6		
- Pe	ercentage of shares (as a % of the total share						
	apital of the company)	1.14%	1.20%	4.11%	1.2		
b) Nor	n-encumbered						
	umber of shares	63,929,759	(2 979 500	24 424 455			
	ercentage of shares (as a % of the total	03,727,737	63,878,509	24,426,405	63,878,50		
sh	areholding of promoter and promoter group)	98.46%	98.38%	94.41%	98.38		
- Pe	ercentage of shares (as a % of the total share				70.50		
		72.64%	72.63%	69.44%	72.7		
	pital of the company)		, 2, 0, 5, 0	07,747.0	72.63		
	FOR COMPLAINTS		3 Months ended 3	80/06/2015			
'endin	ng at the beginning of the quarter and remaining	Mil					
inreso	olved at the end of the quarter	Nil					
	red and disposed off during the quarter		25				
lotes							
bove	results have been reviewed by Audit Committee and a	approved by the	Board of Director	s at their = - · ·	ing h =1.1		
3 Aug	ust 2015.	-pproved by tile	poard or Director	s at meir meeti	ing neld on		
		in manufic.					
	tatutory Auditors have carried out Limited Review of the above results. ompany's equity shares of the face value of ₹ 5/- each was split into the equity shares of the face value of ₹ 2/- each						
tatuto	March 2015 Suite lace value of ₹ 5/- each was sp	lit into the equit	y shares of the f	ace value of ₹ 2	/- each		
tatuto ompa		arning ner chare	has been disclose	ed considering in	ncreased		
tatuto ompa uring	march, 2013. Consequently, as required by AS 70, the F:	ming per snore					
tatuto ompa uring umber	r of shares post sub-division, for all periods reported her	e in above.					
tatuto ompa uring umber uring	r of shares post sub-division, for all periods reported her the quarter 57,750 equity shares fully paid-up were allo	e in above.	so of vested star	k ontions purse	ant to Econ		
tatuto ompa uring umber uring	r of shares post sub-division, for all periods reported her the quarter 57,750 equity shares fully paid-up were allo	e in above.	so of vested star	k options pursua	ant to ESOS		
atuto ompa uring umber uring)11, ii	r of shares post sub-division, for all periods reported her	e in above. tted upon exerci pital by ₹0.01 cr	se of vested stoo	k options pursualium by ₹0.28 cr	ant to ESOS		

UMBAI-IND

By order of the Board For Ajanta Pharma Ctd.

Yogesh M. Agrawal Managing Director

7 Previous period's figures have been regrouped wherever

Mumbai, 13 August 2015

Ajanta House, Charkop, Kandivli (West), Mumbai 400 067 India 3 +91 22 66061000 <u>*</u>+91 22 66061200 ≫ info@ajantapharma.com <u>www.ajantapharma.com</u> CIN:L24230MH1979PLC022059

BSE: 532331 Reuters: AJPH.NS

NSE: AJANTPHARM Bloomberg: AJP:IN

Operating Revenue up 22%, PAT up 41%

(Consolidated - 1st Quarter Results, FY 2015-16)

Mumbai, 13th August 2015: Ajanta Pharma Limited, a specialty focused pharmaceutical formulation company reported today its performance for the 1st quarter ended 30th June 2015.

Key financial & performance highlights - Consolidated

- Revenue from operations grew 22% at Rs. 391 cr. against Rs. 322 cr.
- EBITDA growth of 26% at Rs. 123 cr. against Rs. 97 cr., EBITDA at 31% of revenue.
- Profit before tax grew 35% at Rs. 118 cr. against Rs. 87 cr.
- Profit after tax grew 41% at Rs. 84 cr. against Rs. 60 cr., PAT at 21% of revenue.

Key financial & performance highlights - Standalone

- Revenue from operations grew 18% at Rs. 341 cr. against Rs. 287 cr.
- EBITDA growth of 22% at Rs. 110 cr. against Rs. 90 cr., EBITDA at 32% of revenue.
- Profit before tax grew 33% at Rs. 113 cr. against Rs. 85 cr.
- Profit after tax grew 38% at Rs. 81 cr. against Rs. 59 cr., PAT at 24% of revenue.

Commenting on the results, Mr. Yogesh M. Agrawal, Managing Director said "We have delivered another quarter of competitive growth and margin improvement ahead of the market. Our strategy remains focused on strengthening the core of our business which is refining the thrust on brand building, increasing the intensity on R&D and continuous improvement of our executional capabilities. We intend to enhance our focus on R&D in coming year to augment our capabilities which will be essential to deliver sustained growth."

India

For Q1 FY2016, overall India business was Rs. 144 cr., up 21% over Q1 FY2015. Out of this, Indian Branded business was Rs. 128 cr. posting healthy growth of 18% as against the industry growth of 14%. Institution sales was Rs. 16 cr., posting growth of 58% over previous year quarter. During the quarter, 7 new products were launched, out-of-which 2 were first to market.

In the therapeutic segments where we operate, as per IMS MAT June '15, we have posted robust growth of 45% in Cardiology (segment growth of 13%), 46% in Opthalmology (segment growth of 21%), 20% in Dermatology (segment growth of 20%) and 50% in Pain Management (segment growth of 13%).

Emerging Markets

Emerging markets consolidated business grew 22% during Q1 FY2016 with sale of Rs. 239 cr. Africa contributed Rs. 147 cr., grew 29%, Asia contributed Rs. 89 cr., grew 13% and Latin America contributed Rs. 3 cr., a de-growth of 20%. During the quarter, company launched 9 new products in emerging markets.

📭 ajanta pharma limited

Ajanta House, Charkop, Kandivli (West), Mumbai 400 067 India 1 +91 22 66061000 ₹ +91 22 66061200 info@ajantapharma.com www.ajantapharma.com CIN:L24230MH1979PLC022059

Press Release

BSE: 532331 Reuters: AJPH.NS NSE: AJANTPHARM Bloomberg: AJP:IN

Company continues to strengthen its brand presence in various emerging markets it operates in. Company has a pipeline of 1,600+ products under registration paving the way for sustained growth in these markets.

Regulated Markets

Company has recently received 3 more ANDA approvals apart from 2 approvals it had, taking the total approved basket to 5. Company continues to gain market share for its maiden product launched in the US market & propose to launch other 4 products before the end of this financial year. In Q1 FY2016, sale for one single product was Rs. 3 cr. Company has a basket of 25 ANDAs, out of which 20 are awaiting approval from US FDA.

R&D

In order to meet the identified strategic goals of the company we are enhancing the R&D capabilities and capacities. During last 12 months, the head count has gone up from approx. 400 to 500 which is further expected to be ramped up during the year.

As a result of strategically increased focus on R&D, expenses have gone up from Rs. 11 cr. in Q1 FY2015 to Rs. 18 cr. for Q1 FY2016 which is 5% of net sales

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa & India. Many of company's products are first to market and are leading in their sub therapeutic segments.

Company's state of the art R&D centre for formulation development is located at Mumbai, having a team of 500+ people. Company has world class manufacturing facilities - 4 located in India and 1 at Mauritius. One of the manufacturing facilities in India is approved by US FDA, UK MHRA, pre-qualification from WHO, apart from having approval from FDAs of many other countries.

Implementation of new formulation manufacturing facility (oral solids) at Dahej has been completed and is undergoing qualification, after which it will start taking regulatory filing batches. Addition of this facility will ensure that we have adequate capacities to cater to our growths in coming years.

For last 5 years, company has posted healthy performance with its consolidated revenue showing a CAGR of 31% and net profit of 57%.

For more details visit <u>www.ajantapharma.com</u>. You could also follow us on twitter for regular updates - www.twitter.com/ajantapharma

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ajantapharma.com

